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Abstract
Background: a-toxin is one of the major virulence factors secreted by most Staphylococcus aureus strains, which played a
central role in the pathogenesis of S. aureus pneumonia. The aim of this study was to investigate the impact of capsaicin on
the production of a-toxin by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strain USA 300
and to further assess its performance in the treatment of CA-MRSA pneumonia in a mouse model.
Methodology/Principal Findings: The in vitro effects of capsaicin on a-toxin production by S. aureus USA 300 were
determined using hemolysis, western blot, and real-time RT-PCR assays. The influence of capsaicin on the a-toxin-mediated
injury of human alveolar epithelial cells was determined using viability and cytotoxicity assays. Mice were infected
intranasally with S. aureus USA300; the in vivo protective effects of capsaicin against S. aureus pneumonia were assessed by
monitoring the mortality, histopathological changes and cytokine levels. Low concentrations of capsaicin substantially
decreased the production of a-toxin by S. aureus USA 300 without affecting the bacterial viability. The addition of capsaicin
prevented a-toxin-mediated human alveolar cell (A549) injury in co-culture with S. aureus. Furthermore, the in vivo
experiments indicated that capsaicin protected mice from CA-MRSA pneumonia caused by strain USA 300.
Conclusions/Significance: Capsaicin inhibits the production of a-toxin by CA-MRSA strain USA 300 in vitro and protects
mice from CA-MRSA pneumonia in vivo. However, the results need further confirmation with other CA-MRSA lineages. This
study supports the views of anti-virulence as a new antibacterial approach for chemotherapy.
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Introduction
Staphylococcus aureus, a ubiquitous and virulent pathogen, causes
significant morbidity and mortality from a variety of infectious
syndromes ranging from minor skin and soft-tissue infections to
life-threatening deep tissue infections [1]. Over the past three
decades, the incidence of methicillin-resistant S. aureus (MRSA)
infection has dramatically increased worldwide [2]. Historically,
MRSA has traditionally been a nosocomial pathogen. However,
over the past few years, MRSA has emerged as an important cause
of community-associated infections in both paediatric and adult
populations [3,4]. In contrast to health-care-associated MRSA
(HA-MRSA) infections, community-associated MRSA (CA-
MRSA) infections can occur in otherwise healthy individuals [5],
suggesting that these bacterial strains have a greater virulence than
traditional HA-MRSA strains. This notion was confirmed by data
from various animal infection models [6,7] in which prominent
CA-MRSA isolates, such as USA300, are the most prevalent CA-
MRSA strain and account for up to 97% of all CA-MRSA
infections [8]. The enhanced virulence phenotype of USA300 is
largely attributable to the relatively high expression of virulence
factors, such as a-toxin and phenol soluble modulins [6]. The S.
aureus a-toxin is a major cytolytic toxin that is secreted as a soluble
monomer and forms heptameric transmembrane pores in target
cell membranes [9]. The toxin is known to cause the destruction of
a wide-range of host cells, including erythrocytes, epithelial cells,
fibroblasts, and monocytes.
Along with bacteremia, S. aureus pneumonia is one of the most
prevalent S. aureus-mediated diseases, and it occurs in approxi-
mately 13.3% of all invasive staphylococcal infections [10].
Approximately, 50% of the staphylococcal pneumonia isolates
are classified as MRSA and result in a reported mortality as high
as 56% [11,12]. Due to an increasing disease burden and the
declining performance of traditional antimicrobial agents to
combat S. aureus pneumonia, novel therapeutic strategies are
needed. Novel approaches to target virulence as a means of
attenuating disease severity are now in progress [13]. Recently,
Bubeck Wardenburg and colleagues have demonstrated that, with
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negative mutant strains, a-toxin is essential for pathogenesis in a
mouse model of CA-MRSA pneumonia; antibodies to a-toxin
protect mice from experimental CA-MRSA pneumonia [14,15].
Furthermore, Bartlett et al. have shown that a-toxin facilitates the
generation of CXC chemokines by host cells during experimental
S. aureus pneumonia, thereby promoting severe lung inflammation
[16]. Consequently, the substantial contribution of a-toxin to S.
aureus pneumonia suggests that the molecule could be a valuable
target for antitoxin-based therapeutic approaches [17]. Further-
more, virulence factor production in S. aureus is largely under the
control of the accessory gene regulator (Agr) quorum sensing
system [18]. Recent study by Novick’s group has demonstrated
that a peptide inhibitor of Agr induction could reduce virulence in
a murine model [19].
Previous studies have indicated that many natural products
could affect the production of virulence factors by pathogenic
bacteria [20,21]. Capsaicin is one of the active ingredients in red
chilli (Capsicum annuum), which could act as an antimicrobial agent
against bacterial pathogens, for example, the Bacillus spp.,
Helicobacter pylori, etc [22]. One recent study showed that the
sub-bactericidal concentration of capsaicin drastically inhibits
cholera toxin production in various serogroups of Vibrio cholera
[23].
In this study, we evaluate the influence of capsaicin on the
production of a-toxin by the S. aureus strain USA300 and further
assess its potential therapeutic effect on S. aureus pneumonia in a
mouse model.
Results
Inhibition of a-toxin production by capsaicin
The MIC of capsaicin against S. aureus USA300 was 256 mg/L.
As shown in Fig. 1A, subinhibitory concentrations of capsaicin
suppressed the hemolytic activity of the S. aureus culture
supernatants. The hemolytic unit (HU) in capsaicin-free culture
fluid was 4564.3, but when treated with 16 mg/ml of capsaicin,
the HU was reduced to 3.562.2. Markedly, capsaicin decreases
the hemolytic activity of S. aureus USA300 in a dose-dependent
manner (from 2 to 16 mg/ml), and the 50% inhibitory concentra-
tion (IC50) was calculated to be 7.47 mg/ml. Furthermore, these
concentrations of capsaicin have no influence on S. aureus growth
(Fig. 1B); a drug-free culture supernatant preincubated with
16 mg/ml of capsaicin resulted in no differences in the HUs (Data
not shown). Therefore, we may conclude that either less S. aureus
colony forming units (CFUs), or the capsaicin itself, leads to the
decrease in hemolytic activity.
The major toxin secreted by S. aureus is a-toxin, which causes
the hemolysis of rabbit erythrocytes. Consequently, based on the
results of the hemolysis assay, it is reasonable to infer that the
production of a-toxin may be affected by capsaicin. As expected,
the western blot data were well correlated with the results from the
hemolysis assay. The addition of 2 mg/ml of capsaicin resulted in a
visible reduction in a-toxin content, whereas at 16 mg/ml, no
immunoreactive a-toxin antigen could be detected in the
supernatant of the tested strain (Fig. 1C). Moreover, the addition
of 2 to 16 mg/ml of capsaicin has no significant influence on S.
aureus extracellular protein concentration (Fig. 2).
The transcriptional levels of hla (the gene encoding a-toxin) in S.
aureus USA300 cultured in the presence of increasing concentra-
tions of capsaicin were determined using real-time RT-PCR.
Moreover, the expression of virulence factors by S. aureus was
controlled by many regulatory systems. The Agr is one of the best-
characterised global regulatory systems for the regulation of a-
toxin. To evaluate the hypothesis that agr expression contributes to
the differential expression of hla in capsaicin-treated and capsaicin-
free S. aureus cultures, we measured the expression of RNAIII,
which is the effector molecule of the Agr response, which
ultimately interacts with the target genes to regulate transcription
[24]. As shown in Fig. 1D, the transcription levels of these genes
were significantly decreased in the S. aureus USA300 strain upon
treatment with capsaicin. The transcriptional levels of hla and
RNAIII were decreased by 9.0962.9 and 5.5661.3-fold, respec-
tively, when the USA300 strain was cultured with 16 mg/ml of
capsaicin (P=0.0001 and 0.0015, respectively). The mechanisms
of action by which S. aureus controls a-toxin expression are
extremely intricate and involve an interactive, hierarchical
regulatory cascade that includes the products of Agr and other
components [25]. Therefore, this result indicates that the reduced
a-toxin levels may, at least in part, be attributable to the inhibition
of the Agr two-component system induced by capsaicin.
Capsaicin reduces a-toxin-mediated injury of human
alveolar epithelial cells
Bubeck Wardenburg and Schneewind have previously demon-
strated the critical role of a-toxin in human alveolar cell injury, as
S. aureus strains lacking a-toxin do not cause cellular injury [14].
Further, Liang et al. has also proven that a-toxin causes the
significant death of the epithelial cells (A549) in a dose-dependent
manner, with as little as 0.1 mg/ml of a-toxin leading to
approximately 50% cell death [26]. Consequently, capsaicin was
examined for its ability to prevent injury to A549 cells co-cultured
with S. aureus USA300. Upon co-culture with S. aureus USA300,
cell death was apparent, as indicated by an increase in the number
of red fluorescent dead cells, and the cellular morphology of the
live cells was also influenced (Fig. 3A). However, the addition of
16 mg/ml in the co-culture provided protection from S. aureus-
induced cell death (Fig. 3B). As shown in Fig. 3C, the uninfected
cells reveal the stellate nature of the A549 line. Additionally,
cellular injury in this co-culture system was quantified using a
lactate dehydrogenase (LDH) release assay, and the results are
presented as percent cell death. Capsaicin conferred significant
protection across a concentration range from 2 to 16 mg/ml, and
the IC50 was calculated to be 6.53 mg/ml (Fig. 3D).
Capsaicin protects mice from S. aureus pneumonia
Because low concentrations of capsaicin suppress a-toxin
production by S. aureus USA300, we next determined the ability
of capsaicin to protect mice from S. aureus pneumonia. Time-
concentration profiles of plasma for the three single subcutaneous
capsaicin doses are presented in Fig. 4. The maximum
concentrations of capsaicin in plasma (Cmax) were 13.72, 21.9,
and 34.53 mg/ml for doses of 20, 50, and 100 mg/kg, respectively.
The mice were infected intranasally (i.n.) with S. aureus USA300.
At two hours post-infection, we administered PBS or 100, 50, or
25 mg of capsaicin per kg subcutaneously to groups of 15 mice.
The mice were administered additional doses of PBS or capsaicin
at the corresponding concentrations at 12 h after infection and
every 12 h thereafter for a total of five doses. We monitored
mortality, which results from an acute lethal disease secondary to
S. aureus pneumonia over a 72 h time course. As shown in Fig. 5A,
the mice that received 100 mg/kg of capsaicin were significantly
protected from S. aureus pneumonia at 24 h, 48 h and 72 h
(P=0.005, 0.032 and 0.025, respectively). When the mice were
administered 50 mg/kg of capsaicin, they were significantly
protected from mortality for 24 h post-infection (P=0.039); at
25 mg/kg, no significant protected effects were observed (P.0.05).
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we performed a histopathologic analysis of the lungs from S. aureus-
infected mice that had either received 100 mg/kg of capsaicin or a
PBS control at 24 h after infection. Samples of the mice were
blindly analyzed by an observer trained in pathology. Gross
inspection of infected lungs revealed that the animals that received
capsaicin had a more focal infection, as indicated by a reduction in
the dense, red appearance of the tissue (Fig. 5B). As shown in
Fig. 5C, the mice that were treated with PBS showed that the
majority of the airspace was obliterated by inflammatory cell
infiltrates. Notably, the treatment with capsaicin resulted in the
substantial alleviation of the pulmonary inflammatory reaction, as
shown by less accumulation of cellular infiltrates in the alveolar
space.
To clarify the extent of inflammation, we analyzed the
bronchoalveolar lavage (BAL) fluid from mice that intranasally
infected with S. aureus USA 300. Infected mice lead to markedly
neutrophil flow into the airway 24 h post-infection, and the
neutrophils accounted for 62.3613.1% of total leukocytes in the
BAL fluid (Fig. 6A). Following treatment with 100 mg/kg of
capsaicin, the percentage of neutrophils was reduced to
21.766.6%. Further, we detected the IL-1b, IFN-c and TNF-a
level in the BAL fluid of infected mice. Mice that received
100 mg/kg of capsaicin showed decrease in BAL fluid IL-1b, IFN-
c and TNF-a concentration at 24 h post-infection (P=0.007,
0.029 and 0.002, respectively) (Fig. 6B, C and D).
Discussion
Invasive infections caused by MRSA, such as necrotising
pneumonia, are associated with high mortality, and the response
to treatment of these infections with currently available antibiotics
that are active against MRSA is often unsatisfactory [27]. The
clinical cure rates of linezolid and vancomycin from the
randomized and double-blind studies for the treatment of MRSA
nosocomial pneumonia were 59% (36 of 61 patients) and 36% (22
of 62 patients), respectively [28]. In the late 1990s, the emergence
of CA-MRSA clones that display enhanced virulence potentially
related to up-regulated toxin production, has become a worldwide
threat to public health [17]. Consequently, there is an urgent need
to develop novel antimicrobial agents for the prophylaxis and
treatment of the invasive diseases.
Unfortunately, only a few new antibiotics with new mechanisms
of action have been found in the recent past. The mechanisms of
resistance spreading in pathogenic bacterial populations warrant
the discovery of new bacterial targets [29]. Bacteria use an array of
virulence factors to cause disease in the human host; hence, the
inhibition of virulence targets could lead to the development of
new antibacterial molecules with radically new mechanisms of
action and represent an innovative therapeutic concept [30].
Compared with traditional antibiotics, the anti-virulence com-
pounds could have two advantages [31]. First, as most virulence
traits are not essential for bacterial survival, the use of anti-
virulence compounds might apply a milder evolutionary pressure
on the development of resistance. Second, the specificity of the
effect (i.e., activity against bacteria that are causing pathogenesis
via dissemination in the host) should preserve the bacteria that
inhabit the normal flora. By preventing the expression or activity
of virulence factors, the bacteria are less able to colonise the host.
Furthermore, it is thought that this inhibition could allow the host
immune system, including the normal microbiota, to prevent
bacterial colonisation or clear any established infection [32].
One of the challenges facing the development of anti-virulence
drugs is the identification of suitable virulence targets. S. aureus
mutants with hla deletions display defects in the pathogenesis of
corneal or mammary infection in a murine model [33,34].
Furthermore, more recent studies revealed that a-toxin plays a
Figure 1. Capsaicin reduces the production a-toxin by CA-MRSA USA300. (A) HUs of S. aureus culture supernatants grown in the presence
of increasing concentrations of capsaicin. (B) Growth curves of S. aureus USA 300 after exposure to various concentrations of capsaicin. (C) Western
blot analysis of the a-toxin of S. aureus treated with capsaicin. The S. aureus culture supernatants were subjected to SDS-PAGE. After transfer to
polyvinylidene fluoride membranes, the proteins were stained with a specific rabbit antibody against a-toxin. (D) The relative expression levels of hla
and RNAIII in S. aureus USA300 as determined by real-time RT-PCR. (A and D) Data are presented as the average 6 SD of three independent
experiments. A single asterisk (
*) represents P,0.05 and two asterisks (
**) represent P,0.01 as compared with the capsaicin-free culture.
doi:10.1371/journal.pone.0033032.g001
Figure 2. Protein contents in supernatants of S. aureus USA 300. S. aureus USA 300 was grown in the presence or absence of increasing
concentrations of capsaicin. Data are presented as the average 6 SD from three independent experiments.
doi:10.1371/journal.pone.0033032.g002
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caused by CA-MRSA; vaccination against a-toxin protects mice
from lethal USA300 or USA400 pneumonia and reduces the size
of skin lesions caused by USA300 [14,15,35]. Together, these
previous reports support the views that targeting a-toxin during
invasive CA-MRSA infections could be a promising therapeutic
approach.
The development of anti-virulence drugs relies on newly
discovered synthetic or natural small organic compounds that
inhibit the expression or activity of virulence factors [32]. In this
study, we have shown that capsaicin, a natural compound that
exists in red chilli, drastically suppresses the production of a-toxin
by S. aureus without affecting their viability, protects a-toxin-
mediated alveolar epithelial cell injury in vitro and is also able to
prevent the mortality associated with S. aureus pneumonia in a
murine model of infection. As USA300 strain mainly causes skin
and soft tissue infections, this study may not be generalizable as
this study focuses on a single CA-MRSA strain (USA300) and
requires further testing on a wider panel of strains.
It is suggested that anti-virulence drugs could be used in
combination with established or novel antimicrobials in a
synergistic manner to increase the clinical performance and
extend the lifespan of these drugs [30,36]. The subinhibitory
concentrations of protein synthesis-inhibiting antibiotics (i.e.,
clindamycin and linezolid) that suppress the production staphylo-
coccal virulence factors, such as a-toxin, have been well
characterised [37]. Merk et al. [38] reported that three patients
of CA-MRSA pneumonia failed to response to vancomycin
treatment. However, subsequently treated with antimicrobials
inhibiting exotoxin production (linezolid or clindamycin) received
good clinical results. Consequently, the data presented herein
suggest that capsaicin may potentially be useful for the treatment
of S. aureus pneumonia when used in combination with commonly
used antibiotics.
The agr locus of S. aureus plays a significant role in controlling
the expression of S. aureus virulence factors, and is central to the
pathogenesis of staphylococcal disease [39,40]. It has two
transcripts: RNA II and RNA III. RNA II produces four proteins,
AgrB, AgrD, AgrC and AgrA. AgrD is an autoinducer propeptide
(AIP) which is processed and secreted with the aid of AgrB. The
AIP is recognized by membrane receptor AgrC, and phosphor-
ylated AgrC results in a second phosphorylation of AgrA. The
Figure 3. Capsaicin prevents human alveolar epithelial cells from S. aureus induced injury. Live (green)/dead (red) staining of A549
alveolar epithelial cells was imaged using confocal laser scanning microscopy at 6 h after infection with S. aureus. The cells were co-cultured with S.
aureus USA300 in medium (A), co-cultured in the presence of 16 mg/ml of capsaicin (B), or uninfected (C). (D) LDH release by A549 cells was
determined using cells co-cultured with S. aureus USA300 supplemented with the indicated concentrations of capsaicin. The values in panel D
represent the average 6SD of three independent experiments. A single asterisk (
*) indicates P,0.05 and two asterisks (
**) indicate P,0.01 as
compared with the capsaicin-free co-culture.
doi:10.1371/journal.pone.0033032.g003
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RNA II and RNA III. Novick et al. reported that an inhibitory
AIP could block the formation of an experimental murine abscess
[19]. Furthermore, they synthesized and assessed the inhibitory
activities of 10 AIP derivates based on a truncated AIP analogue
[41]. These studies revealed that targeting the Agr system could be
a promising strategy to block S. aureus virulence. In the study, the
transcription of agr locus was inhibited by capsaicin in a dose-
dependent manner. The data indicated that inhibition of agr locus
transcription may be an alternative approach for the development
of drugs that aimed at the Agr two-component system.
Materials and Methods
Ethics statement
All animal studies were conducted according to the experimen-
tal practices and standards approved by the Animal Welfare and
Research Ethics Committee at Jilin University (Approval ID:
20100920-3).
Bacterial strain, culture and reagents
The CA-MRSA strain USA300-TCH1516 was obtained from
the American Type Culture Collection (ATCC) and used
throughout the study. For the in vitro hemolysis, western blot,
extracellular protein concentration and real-time RT-PCR assays,
bacteria were incubated with and without capsaicin in tryptic soy
broth (TSB) to the post-exponential phase (OD 600 nm of 2.5);
thereafter, the culture supernatants were harvested by centrifuga-
tion and filter sterilised with a 0.22 mm acetate syringe filter.
For mouse lung infections, S. aureus was grown at 37uC in TSB
to an OD600 nm of 0.6. The 25-ml culture aliquots were
centrifuged and washed in PBS prior to resuspension. For the
mortality studies, S. aureus was resuspended in 500 ml PBS
(2610
8 CFUs per 30 ml). For the histopathology experiments
and BAL fluid assays, S. aureus was resuspended in 1,000 ml PBS
(1610
8 CFUs per 30 ml). For the cytotoxicity studies, 5 ml of
culture prepared as described above was resuspended in 10 ml of
DMEM medium (Invitrogen, CA, USA), and 100 ml of the
suspension was used per assay well.
Capsaicin was obtained commercially from Sigma-Aldrich (St
Louis, MO, USA). For the in vitro studies, capsaicin stock
solutions of various concentrations were prepared in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich). For the in vivo assays,
capsaicin was resuspended in sterile PBS.
MIC determination
The minimal inhibitory concentrations (MIC) of capsaicin for S.
aureus USA300 were assessed in triplicate using a standard
microdilution method as recommended by the Clinical and
Laboratory Standards Institute [42]. The MIC was defined as
the lowest drug concentration that inhibited growth.
Growth curve assay
Bacteria were cultured at 37uC to an OD value of 0.3 at
600 nm in TSB, and 100 ml volumes of the culture were aliquoted
into five 250 ml Erlenmeyer flasks. Four of the cultures were
supplemented with capsaicin at concentrations of 2, 4, 8, and
16 mg/ml. Following addition of capsaicin, bacteria were grown at
37uC with constant shaking under aerobic conditions and cell
growth was monitored by reading the OD600 nm values at 30 min
intervals.
Hemolysis assay
Hemolytic activity was assessed as described previously [43].
Briefly, 100 ml of washed rabbit erythrocytes (5610
6/ml) was
added to 96-well V-bottom plates (Corning) filled with 100 mlo f
Figure 4. Serum concentrations of capsaicin in mice after a single subcutaneous dose of capsaicin. Mice were killed at different time
points and blood samples were collected. The serum concentrations were fit to a standard curve using the WinNonlin program.
doi:10.1371/journal.pone.0033032.g004
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and incubated for 20 min at 37uC. In addition, 1% saponin
(Sigma) was used as a positive control, and PBS served as a
negative control. Following centrifugation, the OD450 nm of the
supernatant fluid was determined. One unit of hemolytic activity
was defined as the amount of test solution able to liberate half of
the total haemoglobin from the erythrocytes.
Western-blot assay
Samples (25 ml) of the supernatant fluid were loaded on a 12%
sodium dodecyl sulphate-polyacrylamide gel after boiling in
Laemmli sample buffer [44]. The western blot protocol was
performed as described by Qiu et al. [21], and the product guide
for Amersham ECL Western blotting detection reagents. Anti-
bodies to a-toxin were purchased from Sigma-Aldrich.
Figure 5. Capsaicin protects against CA-MRSA pneumonia. (A) Percent mortality of mice infected with S. aureus after treatment with
capsaicin,
* indicates P,0.05 and
** indicates P,0.01. (B) Gross pathological changes and (C) histopathology of S. aureus-infected lung tissue from
mice that were treated with either PBS or capsaicin.
doi:10.1371/journal.pone.0033032.g005
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The culture supernatants were precipitated by adding 100%
trichloroacetic acid (Sigma) to a final concentration of 10%. After
overnight incubation at 4uC, the precipitate was centrifuged at
15,0006g for 20 min at 4uC and finally washed three times with
ice-cold (220uC) ethanol. The aggregated proteins were dried by
using a Speed-Vac for a few minutes. The protein extracts were
dissolved in 0.5 ml of 0.1 M Tris. The protein concentrations were
determined with a Bio-Rad Munich, Germany) protein assay kit
according to the instructions of the manufacturer.
RNA isolation and real-time RT-PCR assay
The RNA was isolated as described previously [45]. Briefly, cells
were harvested using centrifugation (5,0006g for 5 min at 4uC)
and resuspended in TES buffer containing 100 mg/ml lysostaphin
(Sigma-Aldrich). The samples were incubated at 37uC for 10 min
and applied to a Qiagen RNeasy Maxi column to isolate the total
bacterial RNA according to the manufacturer’s directions. The
RNase-free DNase I (Qiagen, Hilden, Germany) was applied to
remove contaminating DNA. The quality, integrity, and concen-
tration of the RNAs were determined using an Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, Calif.) according to
the manufacturer’s instructions. The primer pairs used in real-time
RT-PCR are listed in Table 1. The cDNA was synthesised from
total RNA using the Takara RNA PCR kit (AMV) Ver. 3.0
(Takara, Kyoto, Japan) according to the manufacturer’s instruc-
tions. The PCR reactions were performed in 25-mL reactions using
SYBR Premix Ex Taq
TM (Takara) as recommended by the
manufacturer. The PCR amplification was performed using the
7000 Sequence Detection System (Applied Biosystems, Courta-
boeuf, France). All samples were analysed in triplicate, and the
housekeeping gene, gyrBRNA, was used as an endogenous control.
In this study, the relative quantification based on the relative
expression of a target gene versus the gyrBRNA gene was utilised to
determine the changes in the transcript level between samples.
Figure 6. Percentage of neutrophils and cytokine levels in the BAL fluid. BAL fluids were collected from infected mice that either received
PBS or 100 mg/kg of capsaicin 24 h post-infection. (A) Percentage of neutrophils in the BAL fluid. IL-1b (B), IFN-c (C) and TNF-a (D) concentrations
were detected by ELISA. Data in panels A to D are means 6 SD (n=15). * indicates P,0.05, and ** indicates P,0.01.
doi:10.1371/journal.pone.0033032.g006
Table 1. Primers used for real-time RT-PCR.
Primer Gene Oligonucleotide primer sequence (59–39)
gyrB-F gyrB TTATGGTGCTGGGCAAATACA
gyrB-R gyrB CACCATGTAAACCACCAGATA
hla-F hla TTGGTGCAAATGTTTC
hla-R hla TCACTTTCCAGCCTACT
RNAIII-F RNAIII TTCACTGTGTCGATAATCCA
RNAIII-R RNAIII GGAAGGAGTGATTTCAATGG
doi:10.1371/journal.pone.0033032.t001
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The A549 human alveolar epithelial cells (ATCC CCL 185)
were cultured in DMEM medium supplemented with 10% foetal
bovine serum. Cells were seeded in 96-well plates at a density of
1.5610
4 cells per well. For both assays, A549 cells were cultured in
triplicate with 100 ml of staphylococcal suspension per well in
DMEM medium with the indicated concentrations of capsaicin.
Following incubation at 37uC for 6 h, the cell viability was
measured either by using live/dead (green/red) reagent (Invitro-
gen, CA, USA) or by measuring LDH release using a Cytotoxicity
Detection Kit (LDH) (Roche, Basel, Switzerland) according to the
manufacturer’s directions. Microscopic images of the stained cells
were obtained using a confocal laser-scanning microscope (Nikon,
Japan). The LDH activity was measured on a microplate reader
(TECAN, Austria).
Pharmacokinetics study
The 8-week-old male C57BL/6J mice were obtained from the
Experimental Animal Centre of Jilin University (Changchun,
China).
The mice were administered a single subcutaneous dose of
capsaicin at 20, 50 and 100 mg/kg. Groups of three mice each
were killed at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after
dosing. Blood samples were collected via cardiac puncture.
Capsaicin in the serum was detected by high-performance liquid
chromatography (HPLC). The serum concentrations were fit to a
standard curve using the WinNonlin program (Pharsight,
Mountain View, CA).
Mouse model of intranasal lung infection
For the lung infection, the mice were anaesthetised intraperi-
toneally with ketamine and xylazine and inoculated with 30 mlo f
S. aureus suspension in the left nare. The animals were held upright
to allow recovery and were subsequently observed over the time
course indicated in the figures. All animal experiments were
performed with groups of 15 mice per condition.
To study the effects of capsaicin treatment, animals infected
with S. aureus received scheduled doses of the compound in a
100 ml volume subcutaneously at the indicated concentrations at
2 h post-infection and then at 12-h intervals thereafter for a total
of six doses. The control mice received 100 ml PBS according to
the same schedule.
To evaluate the pathological correlates of pneumonia, infected
animals were euthanised by anaesthesia followed by cervical
dislocation. The lungs were placed in 1% formalin, and the
formalin-fixed tissues were processed, stained with haematoxylin
and eosin, and visualised with light microscopy.
BAL fluid was performed twice by intratracheal instillation of
500 ml of PBS. The lavage fluid was centrifuged, and the
supernatants were used for cytokine measurements. IL-1b, IFN-
c and TNF-a ELISA kits were purchased from Biolegend
(California, USA). Cell pellets were resuspended in 1 ml of PBS
and used for total and differential cell counts. The total cell
number in BAL fluid was counted using a hematology counter
(Sysmex SF 3000, Sysmex Co., Kobe, Japan). Neutrophils in BAL
fluid were counted on cytospin preparations (centrifuged prepa-
rations stained with the Kwik-Diff staining set; Thermo Fisher
Scientific Inc., Pittsburgh, PA, USA). A total of 300 cells were
counted per cytospin.
Statistical analysis
The statistical significance of the mortality studies was assessed
using the Fisher’s exact test; the significance of the results from the
hemolysis, real-time RT-PCR, the LDH release assays, percentage
of neutrophils, and cytokine levels was calculated using the two-
tailed Student t test. A P value of less than 0.05 was considered to
be significant.
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